A Special Initiative  

The company is seeking individual or group investors who are interested in a unique opportunity to improve the treatment of a disease that kills approximately one million children under the age of five annually in under-developed countries. Malaria is a mosquito spread disease that is readily cured if treated early. Unfortunately, a lack of infrastructure often leads to children not receiving care until it is too late. Researchers at the Massachusetts General Hospital (MGH) in Boston are conducting a clinical trial of an inhaled gas (nitric oxide) that has been shown to significantly prolong survival in severe malaria, making treatment possible in cases that would otherwise be hopeless. Nitric oxide gas for medical use is too expensive for widespread use, however, and Whalen Biomedical is developing a device to generate the gas from room air, making it available in unlimited quantity and at low cost. In cooperation with the MGH, we are seeking a Federal grant to persue this activity, but that is a slow process. We would like to accelerate this work and contribute to lessening the impact of malaria on children in under-developed countries.

Please contact us for more information.